BLACK mobile logo

california

community

California’s Antitrust Bill Could Have Serious Consequences for Patients

August 10, 2026

California's Assembly Bill 1776, intended to strengthen antitrust laws, could inadvertently harm patient access to healthcare by creating legal uncertainty around voluntary patient assistance programs that provide free or discounted medications to underinsured individuals. The bill's broad language may cause these charitable programs to be interpreted as illegal "price-setting" arrangements, potentially exposing pharmaceutical companies to costly litigation and forcing them to scale back or eliminate assistance programs. Additionally, the legislation could disrupt clinical trial partnerships, arrangements that make treatments affordable for diseases like HIV/AIDS, and collaborations essential for public health emergency responses.

Who is affected

  • More than 14 million Californians enrolled in Medi-Cal
  • Uninsured and underinsured individuals who rely on patient assistance programs
  • Life sciences companies operating patient assistance programs
  • Researchers and healthcare providers involved in clinical trials
  • Community health centers and local clinics, particularly those serving underserved and rural communities
  • Patients with life-altering diseases such as HIV/AIDS, tuberculosis, and hepatitis B and C

What action is being taken

  • Assembly Bill 1776 is moving through the California legislature in Sacramento to strengthen the state's antitrust laws.

Why it matters

  • This legislation matters because it could fundamentally undermine healthcare access for millions of vulnerable Californians who depend on patient assistance programs to afford necessary medications. The bill's broad antitrust language creates legal risks that may force pharmaceutical companies to divert resources from patient programs to litigation defense, ultimately reducing rather than expanding healthcare access. Furthermore, it threatens California's medical innovation ecosystem by jeopardizing clinical trial partnerships, affordable treatment arrangements for serious diseases, and the state's ability to rapidly respond to future public health emergencies like the COVID-19 pandemic.

What's next

  • No explicit next steps stated in the article

Read full article from source: The San Diego Voice & Viewpoint

California’s Antitrust Bill Could Have Serious Consequences for Patients